Hemophilia: Difference between revisions

No edit summary
No edit summary
Line 1: Line 1:
== Background ==
== Background ==
*Two types (clinically indistinguishable):
 
**Hemophilia A: Factor VIII deficiency
*Two types (clinically indistinguishable):  
**Hemophilia B: Factor IX deficiency
**Hemophilia A: Factor VIII deficiency  
*Substantial proportion of both types arise from spontaneous mutations
**Hemophilia B: Factor IX deficiency  
*X-linked disorders (overwhelmingly a disease of men)
*Substantial proportion of both types arise from spontaneous mutations  
*ICH is most common cause of hemorrhagic death
*X-linked disorders (overwhelmingly a disease of men)  
*Never give NSAIDs or IM injections
*ICH is most common cause of hemorrhagic death  
*Do not give NSAIDs or IM injections  
*Avoid invasive procedures (e.g. central lines, LP (unless give factor replacement therapy))
*Consult hematology if pt has h/o inhibitors
*Consult hematology if pt has h/o inhibitors


==Clinical Features==
== Clinical Features ==
#Hemarthroses
 
##Leads to joint destruction and chronic arthropathy if not adequately treated
#Hemarthroses  
#Hematomas
##Leads to joint destruction and chronic arthropathy if not adequately treated  
##Bleeding into soft tissues or muscle
##Pts can reliably report when bleeding is occurring
###Neck (airway compromise)
#Hematomas  
###Limbs (compartment syndromes)
##Bleeding into soft tissues or muscle  
###Eye (retro-orbital hematoma)
###Neck (airway compromise)  
###Spine (epidural hematoma)
###Limbs (compartment syndromes)  
###Retroperitoneum (iliopsoas bleeds and massive blood loss)
###Eye (retro-orbital hematoma)  
#Mucocutaneous bleeding
###Spine (epidural hematoma)  
##Spontaneous bleeding uncommon from oropharynx, GI tract, epistaxis, or hemoptysis
###Retroperitoneum (iliopsoas bleeds and massive blood loss)  
#CNS
#Mucocutaneous bleeding  
##Intracranial bleeding is most common cause of hemorrhagic death
##Spontaneous bleeding uncommon from oropharynx, GI tract, epistaxis, or hemoptysis  
#CNS  
##Intracranial bleeding is most common cause of hemorrhagic death  
##Subdural hematomas occur spontaneously or with minimal trauma  
##Subdural hematomas occur spontaneously or with minimal trauma  
#Hematuria
#Hematuria  
##Common, usually not serious, source is rarely found
##Common, usually not serious, source is rarely found


== Diagnosis ==
== Diagnosis ==
*Easy bruising or bleeding out of proportion to the history of trauma
 
*Recurrent bleeding into joints and muscles
*Easy bruising or bleeding out of proportion to the history of trauma  
*Recurrent bleeding into joints and muscles  
*Prolonged PTT; normal PT
*Prolonged PTT; normal PT


== Work-Up ==
== Work-Up ==
*Coags
 
**Only helpful for making the dx; once established unlikely to yield new information
*Coags  
**PT - normal
**Only helpful for making the dx; once established unlikely to yield new information  
**PTT - abnormal (unless mild hemophilia)
**PT - normal  
*Head CT
**PTT - abnormal (unless mild hemophilia)  
**If c/o HA, AMS, significant blunt head injury
*Head CT  
*CT A/P
**If c/o HA, AMS, significant blunt head injury  
*CT A/P  
**Back, thigh, groin, or abd pain
**Back, thigh, groin, or abd pain


== Treatment ==
== Treatment ==
===Factor Replacement===
 
*FFP if dx is unknown (contains VIII and IX)
=== Factor Replacement ===
**Each bag raises factor levels by 3-5%
 
*Factor replacement if dx is known
*FFP if diagnosis is unknown (contains VIII and IX)  
**Dose of Factor VIII = weight (kg) x % increased desired x 0.5
**Each bag raises factor levels by 3-5%  
***After initial correction give half this dose q8-12hr
*Factor replacement if diagnosis is known  
***1 IU/kg will increase the plasma concentration by 2%
**Dose of Factor VIII = weight (kg) x % increased desired x 0.5  
**Dose of Factor IX = weight (kg) x % increase desired
***After initial correction give half this dose q8-12hr  
***After initial correction give half this dose 24 hr later
***1 IU/kg will increase the plasma concentration by 2%  
**Dose of Factor IX = weight (kg) x % increase desired  
***After initial correction give half this dose 24 hr later  
***1 IU/kg will increase the plasma concentration by 1%
***1 IU/kg will increase the plasma concentration by 1%


=== Specific Therapy ===
=== Specific Therapy (Factor VIII) ===


{| border="1" cellpadding="2"
{| border="1" cellpadding="2"
|-
|-
! align="left" | TYPE OF BLEEDING
! align="left" | TYPE OF BLEEDING  
! align="left" | INITIAL DOSAGE
! align="left" | INITIAL DOSAGE  
! align="left" | DURATION
! align="left" | DURATION  
! align="left" | COMMENT
! align="left" | COMMENT
|-
|-
| colspan="4" align="left" | '''Skin'''
| colspan="4" align="left" | '''SKIN'''
|-
|-
| align="left" | Abrasion
| align="left" | Abrasion  
| align="left" | None
| align="left" | None  
| align="left" | None
| align="left" | None  
| align="left" | Treat with local pressure and topical thrombin
| align="left" | Treat with local pressure and topical thrombin
|-
|-
| align="left" | Laceration
| align="left" | Laceration  
| align="left" | Usually none; if necessary, treat as minor
| align="left" | Usually none; if necessary, treat as minor  
| align="left" | None
| align="left" | None  
| align="left" | Local pressure and anesthetic with epinephrine may benefit; watch 4 hours after suturing; reexamine in 24 hours
| align="left" | Local pressure and anesthetic with epinephrine may benefit; watch 4 hours after suturing; reexamine in 24 hours
|-
|-
| align="left" | Superficial
| align="left" | <br>
| align="left" | <br/>
| align="left" | <br>  
| align="left" | <br/>
| align="left" | <br>  
| align="left" | <br/>
| align="left" | <br>
|-
|-
| align="left" | Deep
| align="left" | Deep  
| align="left" | Minor bleeding (12.5 mg/kg)
| align="left" | Minor bleeding (12.5 mg/kg)  
| align="left" | Single-dose coverage
| align="left" | Single-dose coverage  
| align="left" | May need hospitalization for observation; repeat may be necessary for suture removal
| align="left" | May need hospitalization for observation; repeat may be necessary for suture removal
|-
|-
| align="left" | Nasal epistaxis
| align="left" | '''EPISTAXIS'''
| align="left" | <br/>
| align="left" | <br>  
| align="left" | <br/>
| align="left" | <br>  
| align="left" | <br/>
| align="left" | <br>
|-
|-
| align="left" | Spontaneous
| align="left" | Spontaneous  
| align="left" | Usually none; may need to be treated as mild bleeding
| align="left" | Usually none; may need to be treated as mild bleeding  
| align="left" | None
| align="left" | None  
| align="left" | Uncommon; consider platelet inhibition; treat in usual manner
| align="left" | Uncommon; consider platelet inhibition; treat in usual manner
|-
|-
| align="left" | Traumatic
| align="left" | Traumatic  
| align="left" | Moderate bleeding (25 mg/kg)
| align="left" | Moderate bleeding (25 mg/kg)  
| align="left" | Up to 5–7 days
| align="left" | Up to 5–7 days  
| align="left" | Trauma-related bleeding can be significant
| align="left" | Trauma-related bleeding can be significant
|-
|-
| colspan="4" align="left" | '''Oral'''
| colspan="4" align="left" | '''ORAL'''
|-
|-
| align="left" | Mucosa or tongue bites
| align="left" | Mucosa or tongue bites  
| align="left" | Usually none; treat as minor if persists
| align="left" | Usually none; treat as minor if persists  
| align="left" | Single dose
| align="left" | Single dose  
| align="left" | Commonly seen
| align="left" | Commonly seen
|-
|-
| align="left" | Traumatic (laceration) or dental extraction
| align="left" | Traumatic (laceration) or dental extraction  
| align="left" | Moderate (25 U/kg) to severe (50 U/kg)
| align="left" | Moderate (25 U/kg) to severe (50 U/kg)  
| align="left" | Single dose; may need more
| align="left" | Single dose; may need more  
| align="left" | Saliva rich in fibrin lytic activity; oral ε-aminocaproic acid (Amicar) may be given at 100 mg every 6 hr for 7 days to block fibrinolysis; check contraindications; hospitalize patients with severe bleeding
| align="left" | Saliva rich in fibrin lytic activity; oral ε-aminocaproic acid (Amicar) may be given at 100 mg every 6 hr for 7 days to block fibrinolysis; check contraindications; hospitalize patients with severe bleeding
|-
|-
| align="left" | '''Soft tissue/muscle hematomas'''
| align="left" | '''Soft tissue/muscle hematomas'''  
| align="left" | Moderate (25 U/kg) to severe (50 U/kg)
| align="left" | Moderate (25 U/kg) to severe (50 U/kg)  
| align="left" | 2–5 days
| align="left" | 2–5 days  
| align="left" | May be complicated by local pressure on nerves or vessels (e.g., iliopsoas, forearm, calf)
| align="left" | May be complicated by local pressure on nerves or vessels (e.g., iliopsoas, forearm, calf)
|-
|-
| colspan="4" align="left" | '''Hemarthrosis'''
| colspan="4" align="left" | '''Hemarthrosis'''
|-
|-
| align="left" | Early
| align="left" | Early  
| align="left" | Mild (12.5 U/kg)
| align="left" | Mild (12.5 U/kg)  
| align="left" | Single dose
| align="left" | Single dose  
| align="left" | Treat as earliest symptom (pain); knee, elbow, ankle more common
| align="left" | Treat as earliest symptom (pain); knee, elbow, ankle more common
|-
|-
| align="left" | Late or unresponsive cases of early hemarthrosis
| align="left" | Late or unresponsive cases of early hemarthrosis  
| align="left" | Mild to moderate (25 U/kg)
| align="left" | Mild to moderate (25 U/kg)  
| align="left" | 3–4 days
| align="left" | 3–4 days  
| align="left" | Arthrocentesis rarely necessary and only with 50% level coverage; immobilization is critical point of therapy
| align="left" | Arthrocentesis rarely necessary and only with 50% level coverage; immobilization is critical point of therapy
|-
|-
| align="left" | '''Hematuria'''
| align="left" | '''Hematuria'''  
| align="left" | Mild (12.5 U/kg)
| align="left" | Mild (12.5 U/kg)  
| align="left" | 2–3 days
| align="left" | 2–3 days  
| align="left" | Urokinase, the fibrinolytic enzyme, is in urine; with persistent hematuria an organic cause should be ruled out
| align="left" | Urokinase, the fibrinolytic enzyme, is in urine; with persistent hematuria an organic cause should be ruled out
|-
|-
| align="left" | Major bleeding
| align="left" | '''Major Bleeding'''
| align="left" | Major bleeding (50 U/kg)
| align="left" | Major bleeding (50 U/kg)  
| align="left" | 7–10 days or 3–5 days after bleeding ceases
| align="left" | 7–10 days or 3–5 days after bleeding ceases  
| align="left" | In head trauma, therapy should be given prophylactically; early CT scan of head recommended for all
| align="left" | In head trauma, therapy should be given prophylactically; early CT scan of head recommended for all
|}
|}


== Source ==
== Source ==
*Tintinalli
*Rosen's


*Tintinalli
*Rosen's <br>


[[Category:Heme/Onc]] <br/>
[[Category:Heme/Onc]]

Revision as of 02:35, 13 October 2011

Background

  • Two types (clinically indistinguishable):
    • Hemophilia A: Factor VIII deficiency
    • Hemophilia B: Factor IX deficiency
  • Substantial proportion of both types arise from spontaneous mutations
  • X-linked disorders (overwhelmingly a disease of men)
  • ICH is most common cause of hemorrhagic death
  • Do not give NSAIDs or IM injections
  • Avoid invasive procedures (e.g. central lines, LP (unless give factor replacement therapy))
  • Consult hematology if pt has h/o inhibitors

Clinical Features

  1. Hemarthroses
    1. Leads to joint destruction and chronic arthropathy if not adequately treated
    2. Pts can reliably report when bleeding is occurring
  2. Hematomas
    1. Bleeding into soft tissues or muscle
      1. Neck (airway compromise)
      2. Limbs (compartment syndromes)
      3. Eye (retro-orbital hematoma)
      4. Spine (epidural hematoma)
      5. Retroperitoneum (iliopsoas bleeds and massive blood loss)
  3. Mucocutaneous bleeding
    1. Spontaneous bleeding uncommon from oropharynx, GI tract, epistaxis, or hemoptysis
  4. CNS
    1. Intracranial bleeding is most common cause of hemorrhagic death
    2. Subdural hematomas occur spontaneously or with minimal trauma
  5. Hematuria
    1. Common, usually not serious, source is rarely found

Diagnosis

  • Easy bruising or bleeding out of proportion to the history of trauma
  • Recurrent bleeding into joints and muscles
  • Prolonged PTT; normal PT

Work-Up

  • Coags
    • Only helpful for making the dx; once established unlikely to yield new information
    • PT - normal
    • PTT - abnormal (unless mild hemophilia)
  • Head CT
    • If c/o HA, AMS, significant blunt head injury
  • CT A/P
    • Back, thigh, groin, or abd pain

Treatment

Factor Replacement

  • FFP if diagnosis is unknown (contains VIII and IX)
    • Each bag raises factor levels by 3-5%
  • Factor replacement if diagnosis is known
    • Dose of Factor VIII = weight (kg) x % increased desired x 0.5
      • After initial correction give half this dose q8-12hr
      • 1 IU/kg will increase the plasma concentration by 2%
    • Dose of Factor IX = weight (kg) x % increase desired
      • After initial correction give half this dose 24 hr later
      • 1 IU/kg will increase the plasma concentration by 1%

Specific Therapy (Factor VIII)

TYPE OF BLEEDING INITIAL DOSAGE DURATION COMMENT
SKIN
Abrasion None None Treat with local pressure and topical thrombin
Laceration Usually none; if necessary, treat as minor None Local pressure and anesthetic with epinephrine may benefit; watch 4 hours after suturing; reexamine in 24 hours




Deep Minor bleeding (12.5 mg/kg) Single-dose coverage May need hospitalization for observation; repeat may be necessary for suture removal
EPISTAXIS


Spontaneous Usually none; may need to be treated as mild bleeding None Uncommon; consider platelet inhibition; treat in usual manner
Traumatic Moderate bleeding (25 mg/kg) Up to 5–7 days Trauma-related bleeding can be significant
ORAL
Mucosa or tongue bites Usually none; treat as minor if persists Single dose Commonly seen
Traumatic (laceration) or dental extraction Moderate (25 U/kg) to severe (50 U/kg) Single dose; may need more Saliva rich in fibrin lytic activity; oral ε-aminocaproic acid (Amicar) may be given at 100 mg every 6 hr for 7 days to block fibrinolysis; check contraindications; hospitalize patients with severe bleeding
Soft tissue/muscle hematomas Moderate (25 U/kg) to severe (50 U/kg) 2–5 days May be complicated by local pressure on nerves or vessels (e.g., iliopsoas, forearm, calf)
Hemarthrosis
Early Mild (12.5 U/kg) Single dose Treat as earliest symptom (pain); knee, elbow, ankle more common
Late or unresponsive cases of early hemarthrosis Mild to moderate (25 U/kg) 3–4 days Arthrocentesis rarely necessary and only with 50% level coverage; immobilization is critical point of therapy
Hematuria Mild (12.5 U/kg) 2–3 days Urokinase, the fibrinolytic enzyme, is in urine; with persistent hematuria an organic cause should be ruled out
Major Bleeding Major bleeding (50 U/kg) 7–10 days or 3–5 days after bleeding ceases In head trauma, therapy should be given prophylactically; early CT scan of head recommended for all

Source

  • Tintinalli
  • Rosen's